TEST:

HTG Transcriptome Panel

It is feasible to determine consensus molecular subtypes of MIBC from FFPE samples. Classification is reliable also when employing reduced gene sets. In addition, consensus molecular subtypes exhibit a predictive value and might help with therapy decisions as the Ba/Sq subtype shows poorer OS, but seems to benefit more from platinum-based adjuvant chemotherapy.

ChILI has a different gene expression profile and immune cell distribution than AIH, supporting the notion that they are two distinct disease entities. However, both diseases share a similar T-cell repertoire architecture in liver biopsies. Interestingly, we detected overlapping T cell clones between ChILI and matched tumor samples, suggesting a role for shared epitopes between liver and tumor samples.

Notably, a 167-gene predictive signature was developed and validated in the phase II ipilimumab plus nivolumab salivary gland cancer trial. Correlative analysis of the phase II axitinib plus avelumab trial revealed potential biomarkers predictive of combination clinical benefit in ACC, including a gene-expression signature. These findings may guide patient stratification for combinatorial therapy.

ChILI has a different gene expression profile and immune cell distribution than AIH, supporting the notion that they are two distinct disease entities. However, both diseases share a similar T-cell repertoire architecture in liver biopsies. Interestingly, we detected overlapping T cell clones between ChILI and matched tumor samples, suggesting a role for shared epitopes between liver and tumor samples.

Background: KRAS G12C inhibitors (G12Ci) are revolutionizing the therapeutic landscape of advanced NSCLC, but mechanisms of limited clinical efficacy observed in some patients (pts) merit continued exploration. Co-mutations in KEAP1 and STK11 and NRF2 signaling define a subgroup of KG12C NSCLC pts with markedly distinct outcomes upon treatment with ada. The mTORi and ada combination shows high efficacy for targeting KG12C NSCLC harboring KEAP1 and STK11 co-mutations. The clinical safety and efficacy of mTORi nab-sirolimus and ada will be determined in the ongoing KRYSTAL-19 trial (NCT05840510).

LMO2 ISH by RNAscope method is reliable and can be applied in routine FFPE samples. Our series had good correlation with LMO2 gene expression and LMO2 IHC. Moreover, the prognostic impact on survival captured by LMO2 RNA ISH was similar to published for gene expression and IHC methods.

Determination of consensus molecular subtypes of MIBC from FFPE samples is feasible using various RNA sequencing methods. Inconsistent classification mainly involves the stroma-rich molecular subtype, which may be the consequence of sample heterogeneity with (stroma)-cell sampling bias and highlights the limitations of bulk RNA-based subclassification. Classification is still reliable when analysis is reduced to selected genes.

Clinical outcomes to axitinib plus avelumab were distinct between ACC-I and ACC-II subtypes, with ACC-II pts demonstrating an improved DCR and significantly longer PFS. Gene expression analysis revealed high expression of immune function-related genes in patients who benefited from axitinib plus avelumab in both ACC subtypes, indicating possible biomarkers predictive of benefit from the combination in ACC. Clinical trial information: NCT03990571.

"HTG Molecular Diagnostics, Inc...today announced there will be at least four scientific posters featuring its proprietary HTG EdgeSeq™ technology presented at the American Association for Cancer Research Annual Meeting (AACR) April 16-19 in Orlando, Florida."

IL23 is an especially appealing target given it is tumourogenic, has a favourable side effect profile and is effective in conventional inflammatory bowel disease (IBD). Further studies are needed to elucidate the role of anti-IL23 therapies in patients with CPI-colitis.

In conclusion, basal-like MIBC and the squamous histological subtype are associated with high nuclear KMT9α expression. The association with poor survival makes it a potential target for the treatment of bladder cancer.

"HTG Molecular Diagnostics, Inc...today announced there will be at least eight scientific abstracts featuring HTG’s proprietary HTG EdgeSeq™ technology presented at the 45th Annual San Antonio Breast Cancer Symposium (SABCS 2022) and at the 64th Annual American Society of Hematology (ASH) Annual Meeting."

"HTG Molecular Diagnostics, Inc...and OmiCure®, a leading European digital health company that develops and markets explainable AI-based therapeutic decision support software, announced a collaboration with OmiCure to implement the HTG Transcriptome Panel (HTP) as an alternative to RNA-Seq to inform the OmiCure test and help guide therapeutic decision-making across several cancer types."

"HTG Molecular Diagnostics...announced the customer publication of a peer reviewed journal article featuring the HTG Transcriptome Panel (HTP) less than one year after the breakthrough product’s commercial release...The article, published in Frontiers in Medicine by one of several participants in the Company’s HTP Early Adopter Program, applied the comprehensive HTP to query 19,398 mRNA targets in an effort to advance the understanding of how best to treat bladder cancer patients who do not fall into categories identified by routine tissue staining."

"HTG Molecular Diagnostics, Inc...announced its HTG EdgeSeq technology was highlighted in multiple scientific abstracts at the 2022 American Society of Clinical Oncology (ASCO) conference held in Chicago, Illinois...Abstracts were presented by HTG’s key biopharma customers and scientific collaborators from both the United States and Europe highlighting the unique features, benefits and results utilizing HTG’s proprietary HTG EdgeSeq gene expression profiling (GEP) technology. Prominent among the research presented was the HTG Transcriptome Panel (HTP). The HTP, released for commercial use in August 2021, enables the capture of comprehensive and reliable human transcriptome data using a fraction of the sample typically required by other GEP methods." "

Additionally, a cohort of 83 breast cancer FFPE samples, that had also been evaluated for estrogen (ER) and progesterone (PR) receptor expression by immunohistochemistry (IHC), were used to determine the correlation between HTP gene expression and orthogonal IHC data... The results demonstrate the HTP is a powerful tool for comprehensive gene expression analysis that addresses several key limitations of RNA-Seq. The HTP is precise, accurate, user-friendly (avoids extraction-bias, fewer steps, automated data analysis), and efficient (quicker, requires lower amounts of sample, works well with samples of low quality and archival samples). Collectively, the data demonstrate HTP has the potential to be used for biomarker discovery and the development of clinical solutions.

"HTG Molecular Diagnostics, Inc...announced that it has improved the sample preparation protocol for its miRNA Whole Transcriptome Assay (miRNA WTA) so that it is now harmonized with the HTG Transcriptome Panel (HTP)...The harmonized protocol is designed to enable customers to process a single sample with HTG’s nearly 20,000 gene mRNA and 2,000+ miRNA transcriptome panels using a single sample lysate."

"HTG Molecular Diagnostics, Inc...expanded the potential markets and applications for its pioneering HTG Transcriptome Panel (HTP). Since launching HTP with commercial availability in the US and Europe in August 2021, HTG has completed validation of additional sample types that are more commonly used outside of oncology, and also expanded sequencing capabilities to facilitate easier testing of larger sample cohorts...Initially validated for neoplastic tissue, HTG has now validated HTP for use with normal FFPE tissue and other non-neoplastic tissues. In addition, the panel has been validated with PAXgene, a popular liquid blood-based sample type, and with extracted RNA from both fresh frozen and FFPE tissue samples."

"HTG Molecular Diagnostics, Inc...announced that it has exceeded $1 million of revenue recognized from sales of its HTG Transcriptome Panel (HTP) as of November 30, 2021. HTP was launched with commercial availability in the United States and Europe in early August 2021."

"HTG Molecular Diagnostics...and the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai)...announced they have entered into a new research collaboration as part of HTG’s Transcriptome Panel Early Adopter Program. HTG will provide in-kind laboratory services utilizing its proprietary HTG EdgeSeq technology in connection with multiple Icahn Mount Sinai bladder cancer studies."